Comparative Pharmacology
Head-to-head clinical analysis: ANESTACON versus ZTLIDO.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ANESTACON versus ZTLIDO.
ANESTACON vs ZTLIDO
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Local anesthetic that stabilizes the neuronal membrane by inhibiting sodium ion influx, thereby blocking nerve impulse conduction.
ZTLIDO (lidocaine) is a sodium channel blocker that binds to voltage-gated sodium channels in neuronal membranes, stabilizing the membrane and inhibiting the initiation and conduction of nerve impulses, thereby producing local anesthesia.
5% lidocaine ointment, apply topically 3-4 times daily as needed; maximum single dose 20 g of ointment (1 g lidocaine), maximum total daily dose 60 g (3 g lidocaine).
1.8% lidocaine topical patch: Apply up to 3 patches at once to intact skin for up to 12 hours in a 24-hour period.
None Documented
None Documented
Terminal elimination half-life is 1.5–2.5 hours; clinically relevant for dosing interval.
Terminal elimination half-life is 1.5 to 2.0 hours in patients with normal renal function; prolonged in renal impairment (up to 6-8 hours with CrCl <30 mL/min).
Renal (90% as unchanged drug and metabolites; 10% fecal/biliary).
Primarily renal excretion as unchanged drug (80-85%) and metabolites (10-15%); less than 5% excreted in feces.
Category C
Category C
Topical Anesthetic
Topical Anesthetic